Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Pablo Bousquets-Muñoz *Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.ORCID 0000-0002-2969-008X
Oscar Molina *Josep Carreras Leukemia Research Institute, Barcelona, Spain.ORCID 0000-0001-7585-4519
Ignacio VarelaInstituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain.ORCID 0000-0002-0969-506X
Ángel Álvarez-EguiluzLaboratorio de Oncología Molecular, Laboratorio de Medicina, Instituto Universitario de Oncología (IUOPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
Javier Fernández-MateosDepartamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.
Ana GómezDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Autonomous University of Madrid, Madrid, Spain.
Elena G SánchezUnidad de Terapias Avanzadas, Laboratorio de Oncohematología, Fundación para la Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Milagros BalbínLaboratorio de Oncología Molecular, Laboratorio de Medicina, Instituto Universitario de Oncología (IUOPA), Hospital Universitario Central de Asturias, Oviedo, Spain.
David RuanoDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Autonomous University of Madrid, Madrid, Spain.
Manuel Ramírez-OrellanaDepartment of Pediatric Hematology and Oncology, Hospital Infantil Universitario Niño Jesús, Autonomous University of Madrid, Madrid, Spain.ORCID 0000-0003-0332-6973
Xose S Puente *Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain. xspuente@uniovi.es.ORCID 0000-0001-9525-1483
Pablo Menéndez *Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. pmenendez@carrerasresearch.org.
Talia Velasco-Hernandez *Josep Carreras Leukemia Research Institute, Barcelona, Spain. tvelasco@ub.edu.ORCID 0000-0003-2183-7443
Funding
Ministerio de Economía y Competitividad (Ministry of Economy and Competitiveness) PID2020-117185RB-I00Ministry of Economy and Competitiveness | Secretaría de Estado de Investigación, Desarrollo e Innovación (Secretary of State of Research, Development and Innovation) PID2022-142966OB-I00
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML. · full record | OpenQuestion